• Product Suite
    Product
    • Overview
    • AD Workbench
    • AD Data Initiative Repository
    • Federated and Distributed Data Sharing Appliance (FDSA)
    • Additional Collaboration Tools

    Resource
    • Explore Data
    • Contribute Data
    • Support
  • Scientific Strategy
    • Overview
    • Case Studies
  • Accelerating Research
    • Overview
    • AI Explorations
    • Fellowship
    • Data Challenges
  • About
    • Overview
    • Advisors & Team
    • Announcements & Updates
    • Newsletters
  • Log in
  • Sign up
  • Explore Data
Log in Sign up Explore Data
Newsletter

Driving Discovery: New Opportunities to Advance ADRD Research

Wednesday, October 1

The Alzheimer's Disease Data Initiative (ADDI)

A note from Niranjan Bose, Executive Director of AD Data Initiative

As we move into the fall, I want to update you on two exciting new projects the AD Data Initiative coalition is working on. 

 

As always, we continue to add more valuable datasets to the AD Discovery Portal, but we are also coming up with new ways to encourage more researchers to use our tools in more impactful ways. Specifically, in the coming months, we are launching a new data challenge and a scientific competition to accelerate innovation and discovery at the frontiers of ADRD research.  

 

Over the summer, I told you about the public release of the Global Neurodegeneration Proteomics Consortium’s V1 (GNPC) harmonized dataset: with nearly 250 million unique protein measurements and 35,000 patient bio-samples within, it is one of the largest disease-specific proteomics datasets ever created. 

 

Next month, to spur more researchers from all backgrounds to engage with this awesome resource, we are launching the GNPC Data Challenge, which will offer $10k and $5k cash prizes to the researchers who best leverage GNPC’s dataset to answer one of six priority research questions (listed below). Don’t see your favorite question listed? Submit your suggestion and we might add it to the list.

 

In addition, we also recently announced a $1 million Alzheimer's Insights AI Prize (AlzInsights AI Prize) for ADRD research. This is a global competition to find new, AI-driven solutions that can speed up our fight against Alzheimer’s and is made possible through the generosity of one of our founders, Bill Gates. 

 

As I and several others recently argued in Nature Medicine, all evidence suggests that agentic AI can redefine what’s possible for ADRD research and open new paths to prevention, diagnosis and care. We are now reviewing the many creative and inspired submissions we received and will announce the semi-finalists for the AlzInsights AI Prize in October.

 

Our goal as an initiative is not data for the sake of data. It is data for the sake of discovery, solutions and impact. We have learned from previous data challenges that they help mobilize ADRD scientists and generate both more collaboration and “outside the box” thinking about critical avenues for innovation. So, we very much look forward to seeing what teams come with for both these contests and expect big things from our global ADRD research community.

 

With that in mind, and in the spirit of World Alzheimer’s Day 2025, which we celebrated this September, I want to applaud all of you for everything you’re doing to improve the lives of ADRD sufferers and hasten the end of this terrible disease. We could not do any of this important work without you.

 

Best,

 

Niranjan Bose

Interim Executive Director

Alzheimer's Disease Data Initiative

 

P.S. If you know someone who would like to learn more about our work, please share this newsletter, and invite them to subscribe here.

 

ANNOUNCEMENTS

GNPC Data Challenge Launching in October: In October, we will be announcing a new data challenge encouraging researchers to take advantage of the groundbreaking Harmonized Data Set V1 by the Global Neurodegeneration Proteomics Consortium, which includes nearly 250 million unique protein measurements from 35,000 biosamples across more than 20 international cohorts. Specifically, we are encouraging participants to analyze the HDS V1 results for answers to the following priority research questions:

 

  • How can protein changes over time help track aging and disease progression? Do protein changes help mark pre-clinical and post-diagnosis AD?

  • Do changes in plasma markers influence or underpin speed of progression of disease? Are any markers promising as treatment targets?
  • Can we develop prognostic markers of cognitive decline and neurodegeneration?
  • How can we leverage biomarker data to classify subtypes of Alzheimer’s disease?
  • Can proteomics help identify novel ways to delay the onset of disease?
  • How can we leverage proteomics for early diagnosis?

 

If you believe there is another priority research question we should consider, submit it before November 1! We will choose up to two more questions to be added to the list. The top two entries per question will receive cash prizes of $10k and $5K respectively, plus publishing fees. Researchers must leverage the HDS V1 and can additionally analyze Bio-Hermes, Emory Goizueta ADRC, KU ADRC and MCSA datasets.

 

Entrants must perform their analyses in AD Workbench, and address one of the priority research questions above. Winners will be judged based on the significance of their findings to the field, innovation, and responsiveness to the question they have chosen. Contestants do not need to register and can simply submit a 2-page summary of their results before Jan 15, 2026.

 

AlzInsights AI Prize Submissions Received: On August 19, we also initiated a competition to accelerate the pace of AD discovery and development by harnessing artificial intelligence (AI), with a $1 million first prize for the agentic AI solution that can generate the most powerful leap in the pace, scale and reach of ADRD research. By September 12, we received over 175 submissions from researchers around the world. 

 

Up to eight semi-finalist teams will be announced in October and will present at a pitch event following the Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Diego in December. The three finalist teams chosen thereafter will be invited to a final presentation event timed around the 2026 AD/PD International Conference in Copenhagen next March.
 

World Alzheimer’s Day 2025: On September 21, the AD Data Initiative Coalition marked this year’s World Alzheimer’s Day. A huge thanks to all of our colleagues and partners working to better understand, diagnose and treat Alzheimer’s Disease and improve the lives of the 55 million people worldwide suffering from it.

 

NEW DATASETS NOW ACCESSIBLE VIA AD WORKBENCH

We published several new datasets to AD Workbench this quarter, bringing our total to 126, all findable and accessible through the AD Discovery Portal. New datasets include:

 

GNPC HDS: In July, the long-awaited Harmonized Data Set V1 from the Global Neurodegeneration Proteomics Consortium became publicly available to all users of AD Workbench. Featuring nearly 250 million unique protein measurements and 35,000 biosamples from more than 20 international cohorts, the GNPC HDS is one of the largest-known disease-specific datasets ever created. Since its launch, the GNPC HDS has already been requested over 250 times by ADRD researchers, which is about a third of our total data access requests made in 2025 to date. 


GNPC Cohorts: Several of the cohorts involved in the development of the GNPC HDS V1 have offered additional useful metadata and variables that have also been added to AD Workbench, including teams from Emory University, the University of Kansas, the Mayo Clinic, and Washington University in St. Louis.
 

Bio-Hermes-001: Bio-Hermes-001 is a platform study that compared the results of blood and digital biomarker tests, including digital cognitive and voice assessments, with the results of brain amyloid PET scans and traditional cognitive tests collected across a study population of which 24% of participants were from traditionally underrepresented communities.

 

AD-linked R47H-TREM2 mutation induces disease-enhancing microglial states via AKT hyperactivation: This study includes droplet-based single nuclear RNA sequencing of frontal cortical tissues from AD patients with and without the TREM2-R47H mutation and their age, pathology, and sex-matched controls. It identified enrichment of a disease-enhancing, proinflammatory subpopulation of microglia in human AD patient brains with the R47H-TREM2 mutation and uncovered that enhanced Akt signaling in microglia underlies the proinflammatory cytokine state and synaptic toxicity in the R47H-TREM2 tauopathy mouse model.

 

North African Dementia Registry (NADR)-Egypt cohort: The aim of this project is to strengthen research capabilities in dementia research in Africa by creating a multinational dementia registry, beginning with Egypt. Eventually, the registry will expand to encompass other African countries, with a specific focus on Morocco. This project outlines the framework, design, impact, and scalability of the cohort, while also showcasing the potential for replication in other African nations and integration into the Davos Alzheimer's Collaborative (DAC) Global Cohorts.

 

BORCS6 KD transcriptomics on iNeurons: This study characterizes the effect of BORCS6 KD on the iPSC-derived neuron transcriptome and provides RNA sequencing files from analyses of neurons on day 7 post dox induction WTC11 neurons and neurons containing a non-targeting sgRNA or BORCS6 KD. 

 

UPCOMING EVENTS: Q4 2025

AlzPI 2025
3 October 2025
Dublin, OH

 

Alzheimer Europe 
6-8 October 2025
Bologna, Italy

 

ASIC 2025
12-14 November 2025
San Francisco, CA


CTAD 2025
1-4 December 2025
San Diego, CA

 

ADI End of Year Forecast
10 December 2025
London, England

 
Photo of Geometric architecture.

Learn more at AlzheimersData.org

  • News
  • Contact Us
  • FAQs

Receive our quarterly newsletter and latest announcements.


©Alzheimer's Disease Data Initiative 2026

  • Privacy
  • Terms